Sex hormones, brain damage and clinical course of Multiple Sclerosis

Tomassini, Valentina; Pozzilli, Carlo

doi:10.1016/j.jns.2009.04.014

Cited by 48 publications

(40 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results could thus suggest a promotion of repairing and neuroprotective mechanisms associated with OC use. This interpretation is supported by experimental and clinical data indicating that sex hormones may have protective effects on brain damage and repair mechanisms in these patients [3][4][5]. All oestrogens are not exactly alike [5,23].…”

Section: P-valuementioning

confidence: 64%

“…A higher prevalence of women with the RR-MS and a female-specific increase in the incidence of the disease has been documented, mainly from an increase in the number of female patients with RR-MS [2]. Gender-related differences in clinical severity, immunological features and brain damage have also been reported, suggesting an effect of sex hormones [3,4]. Moreover, in mice with experimental autoimmune encephalomyelitis (EAE), the animal model of MS, treatment with sex hormones is able to protect against the development of the disease or reduce the severity of its clinical signs [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oral contraceptive use and clinical outcomes in patients with multiple sclerosis

Sena¹,

Couderc²,

Vasconcelos³

et al. 2012

Journal of the Neurological Sciences

View full text Add to dashboard Cite

Experimental and clinical data suggest a role of sex steroids in the pathogenesis of multiple sclerosis (MS). Scant information is available about the potential effect of oral contraceptive (OC) use on the prognosis of the disease. We aimed to evaluate this. The study population consisted of 132 women with relapsing-remitting MS before receiving disease modifying treatment and a mean disease duration 6.2 (SD 5.1) years. Three groups of patients were distinguished according to their OC behavior: [1] never-users, patients who never used OC [2] past-users, patients who stopped OC use before disease onset, and [3] after-users, those who used these drugs after disease onset. Multiple linear and logistic regression models were used to analyze the association between oral contraceptive use and annualized relapse rates, disability accumulation and severity of the disease. After-user patients had lower Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Severity Score (MSSS) values than never users (p b 0.001 and p = 0.002, respectively) and past users (p = 0.010 and p = 0.002, respectively). These patients were also more likely to have a benign disease course (MSSS b 2.5) than never and past users together (OR: 4.52, 95%CI: 2.13-9.56, p b 0.001). This effect remained significant after adjustment for confounders, including smoking and childbirths (OR: 2.97, 95%CI: 1.24, 6.54, p = 0.011 and for MSSS β: − 1.04; 95% C.I. − 1.78, − 0.30, p = 0.006). These results suggest that OC use in women with relapsing-remitting MS is possible associated with a milder disabling disease course.

show abstract

Section: P-valuementioning

confidence: 64%

Section: Introductionmentioning

confidence: 99%

Oral contraceptive use and clinical outcomes in patients with multiple sclerosis

Sena¹,

Couderc²,

Vasconcelos³

et al. 2012

Journal of the Neurological Sciences

View full text Add to dashboard Cite

show abstract

“…It increases the propagation and differentiation of oligodendrocyte precursor cells that play an major role in remyelination after toxin-secreted lesions and aging. In addition to neuronal and myelinating effects, progesterone may modify the immune system, shifting a Th1 pro-inflammatory response to a Th2 anti-inflammatory response (Tomassini et al, 2009). Finally, prolactin is a neuroendocrine peptide with strongly immunomodulatory characteristics.…”

Section: Discussionmentioning

confidence: 99%

Study effect of IL-35 and some sex hormones in male patients who have multiple sclerosis (MS)

Bidan

Hamzah²

2015

IJAC

View full text Add to dashboard Cite

<p>Multiple sclerosis (MS) is a disease characterized by inflammation and demyelination. Currently, the cause of MS is unknown. An early and accurate diagnosis of multiple sclerosis (MS) is very important, since it allows early treatment initiation, which reduces the activity of the disease. The present study aimed to focus a light on the contribution of interlukin-35 (IL-35) and its relation to some hormones such as testosterone, progesterone, and prolactin (PRL) in the pathogenesis of multiple sclerosis. Twenty two enrollers (samples) attended from Teaching hospital of Baghdad were divided into two groups. Ten enrollers were described as healthy subject as control group as group 1 (G1) in range ages (20-30) years. Twelve male patients as group 2 (2) have been relapsing remitting multiple sclerosis (RRMS) matched in age with group 1 (G1).</p>

show abstract

“…Osim na prevalencu, pol utiče i na klinički tok, težinu i simptomatologiju MS (37,41). Naime, iako su žene podložnije obolevanju od MS, one češće imaju benigniji tok bolesti (RRMS), dok muškarci češće boluju od MS sa primarno progresivnim tokom (PPMS) (14).…”

Section: Polne Razlike U Epidemiološkim I Kliničkim Karakteristkama Msunclassified

Sex differences in the clinical presentation and therapy of multiple sclerosis

Nacka-Aleksić¹

2016

Arh farmaciju

View full text Add to dashboard Cite

Kratak sadržajMultipla skleroza (MS) se češće javlja kod žena nego kod muškaraca i disproporcija između obolevanja žena i muškaraca od ove bolesti pokazuje tendenciju stalnog rasta. Pol ima kritičnu ulogu u razvoju, progresiji, kliničkim manifestacijama MS i odgovoru na terapiju. Ove razlike su, najverovatnije, posledica delovanja genetskih, epigenetskih i hormonskih faktora, razlika u izloženosti pojedinim sredinskim faktorima, kao i bioloških razlika između imunskog i nervnog sistema žena i muškaraca. Polne razlike u svim ovim aspektima se moraju uzeti u obzir prilikom dizajniranja i tumačenja rezultata istraživanja vezanih za patogenezu MS, a posebno prilikom razvoja novih terapijskih strategija i kliničkih istraživanja lekova namenjenih lečenju ove bolesti. Razumevanje mehanizama koji stoje u osnovi polnih razlika u patogenezi i/ili odgovoru na terapiju u MS bi moglo biti relevantno i za širi spektar autoimunskih bolesti u kojima je izražen polni dimorfizam u incidenci i prevalenci i/ili kliničkim manifestacijama bolesti.Ključne reči: polne razlike, multipla skleroza, DMT

show abstract

Sex hormones, brain damage and clinical course of Multiple Sclerosis

Cited by 48 publications

References 82 publications

Oral contraceptive use and clinical outcomes in patients with multiple sclerosis

Oral contraceptive use and clinical outcomes in patients with multiple sclerosis

Study effect of IL-35 and some sex hormones in male patients who have multiple sclerosis (MS)

Sex differences in the clinical presentation and therapy of multiple sclerosis

Contact Info

Product

Resources

About